|Articles|March 15, 2003
- BioPharm International-03-01-2003
- Volume 16
- Issue 3
Inside Washington: The Big Shift
Author(s)Jill Wechsler
Jill Wechsler FDA explains its plan for moving most biologics under the authority of CDER. But a big question remains: What will the change do to approval times?
Advertisement
Articles in this issue
over 22 years ago
Biotech World: India Blossomsover 22 years ago
Outsourcing Outlook: One-Stop Shopsover 22 years ago
Qualification of a Chromatographic Column: Why and How to Do Itover 22 years ago
Guest Editorial: Recruiting Biotech Talentover 22 years ago
Survival Strategies: How to Purchase COTS SoftwareNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
